Clinical Trial Update: Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating adverse events and change in disease activity when livmoniplimab is used in combination with budigalimab in adults with urothe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Livmoniplimab
• budigalimab (budigalimab)

Snippet

Sponsor: AbbVie | Conditions: Urothelial Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING